rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NGNE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Neurogene at stifel 2026 healthcare conference: rett drug advances
      Nov 11Investing.comNGNESF
      Neurogene at Guggenheim healthcare conference: Rett gene therapy advances
      Nov 10Investing.comNGNE
      Neurogene: Q3 Earnings Snapshot
      Nov 9Yahoo FinanceNGNE
      Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
      Nov 9Yahoo FinanceNGNE
      Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      NEW YORK, November 05, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,010 shares of the Company’s common stock to one new employee (the "Inducement Grant") on November 3, 2026 (the "Grant Date"). The Inducem

      Nov 5Yahoo FinanceNGNE
      Neurogene to Participate in Upcoming Investor Conferences
      Nov 3Yahoo FinanceNGNE
      Neurogene presents preclinical data on Rett syndrome therapy
      Oct 27Investing.comNGNE
      Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
      Oct 27Yahoo FinanceNGNE
      Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
      Oct 20Yahoo FinanceNGNE
      Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Neurogene (NGNE)

      Detailed price information for Neurogene Inc (NGNE-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailARGXNGNE
      Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ)
      Oct 8Seeking AlphaNGNE
      JPMorgan Initiates Neurogene at Overweight With $60 Price Target
      Oct 8Yahoo FinanceNGNE
      JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential
      Oct 8Investing.comNGNE
      Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 5Yahoo FinanceNGNE
      Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
      Sep 11Seeking AlphaNGNETSHA
      Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

      NEW YORK, September 08, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference.

      Sep 8Yahoo FinanceNGNE
      Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEW YORK, September 04, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of the Company’s common stock to two new employees (the "Inducement Grants") on September 1, 2026 (the "Grant Date"). The In

      Sep 4Yahoo FinanceNGNE

      This is the newest page. Registered accounts read further back.